# US 2008/0305077 A1 · Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305077 A1
- Document ID: US20080305077A1
- Status: Published application
- Kind: A1
- Application number: 12/134,385
- Filed: 2008-06-06
- Published: 2008-12-11
- Earliest claimed: 2007-06-08
- Assignees: HealthPartners Research Foundation
- Inventors: William H. Frey, II; Leah Ranae Bresin Hanson; Shyeilla V. Dhuria
- Web page: https://patentgrep.com/patent/US20080305077A1

## CPC

- A61K 38/2006: {IL-1}
- A61K 9/0043: {Nose}
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 38/28: Insulins
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to, inter alia, the CNS applied via intranasal administration while reducing non-target exposure are provided. In certain embodiments, at least one vasoconstrictor is provided intranasally prior to intranasal administration of at least one therapeutic compound. In other embodiments, the vasoconstrictor(s) and therapeutic compound(s) are combined in a pharmaceutical composition and delivered intranasally. The present invention substantially increases targeting of the therapeutic compound(s) to, inter alia, the CNS while substantially reducing unwanted and potentially harmful systemic exposure. The preferred administration of the invention applies the vasoconstrictor(s) and/or therapeutic compound(s) to the upper third of the nasal cavity, though application to the lower two-thirds of the nasal cavity is also within the scope of the invention.

## Claims

### Claim 1

A method for increasing the efficiency of intranasal delivery of at least one pharmaceutical compound to a target in a patient for treatment of a disease or condition of the patient, comprising:
providing at least one therapeutic compound, wherein the target is within the patient's central nervous system;
providing at least one vasoconstrictor;
applying an effective amount of the at least one therapeutic compound and an effective amount of the at least one vasoconstrictor to the nasal cavity of a patient;
delivering at least one therapeutic compound to the target; and
reducing the amount of the at least one therapeutic compound that is absorbed into the blood and/or peripheral tissues.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient condition comprises Alzheimer's disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient condition comprises Parkinson's disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient condition comprises one or more of the following: cerebrovascular disorders, frontotemporal dementia, personality disorders, cognition disorders, motor dysfunction, eating disorders, sleep disorders, affective disorders, anxiety disorders, schizophrenia, brain tumors and ataxia.

### Claim 5 (depends on 1)

The method of claim 1, wherein the target comprises the frontal cortex.

### Claim 6 (depends on 1)

The method of claim 1, wherein the target comprises the hippocampus.

### Claim 7 (depends on 1)

The method of claim 1, wherein the target comprises the hypothalamus.

### Claim 8 (depends on 1)

The method of claim 1, wherein the target comprises the cerebellum or brainstem.

### Claim 9 (depends on 1)

The method of claim 1, wherein the at least one therapeutic compound comprises deferoxamine.

### Claim 10 (depends on 1)

The method of claim 1, wherein the at least one therapeutic compound comprises one or more of the following: insulin, IGF-I, TGFbeta, IL1beta, TNFalpha, TGFbeta, cobalt, pyruvate, oxalacetate and lactate.

### Claim 11 (depends on 1)

The method of claim 1, wherein the at least one therapeutic compound comprises one or more of the following: HC and KTP.

### Claim 12 (depends on 1)

The method of claim 1, wherein the at least one vasoconstrictor comprises PHE and THZ.

### Claim 13

A method for increasing the efficiency of intranasal delivery of at least one pharmaceutical compound to a target in a patient for treatment of a disease or condition of the patient, comprising:
providing at least one therapeutic compound, wherein the target is within the patient's lymphatic system;
providing at least one vasoconstrictor;
applying the at least one therapeutic compound and at least one vasoconstrictor to the nasal cavity of a patient;
delivering the at least one therapeutic compound to the target; and
reducing the amount of the at least one therapeutic compound that is absorbed into the blood and/or peripheral tissues.

### Claim 14 (depends on 13)

The method of claim 13, wherein the condition comprises brain tumors and the method further comprises treating and/or preventing brain tumors.

### Claim 15 (depends on 13)

The method of claim 13, wherein the condition comprises one or more of the following: multiple myeloma, Hodgkin's disease, lymphadenitis, lymphatic filariasis, lymphoma, non-Hodgkin's lymphoma, and thymus cancer.

### Claim 16 (depends on 13)

The method of claim 13, wherein the condition comprises one or more of the following: AIDS, neuroAIDS, SCID, autoimmune diseases, Sjogren's syndrome, lupus and multiple sclerosis.

### Claim 17 (depends on 13)

The method of claim 13, wherein the condition comprises allergies and/or chronic sinusitis.

### Claim 18

A method increasing the efficiency of intranasal delivery of at least one pharmaceutical compound to a target in a patient for treatment of a disease or condition of the patient, comprising:
providing at least one therapeutic compound, wherein the target is within the patient's meninges;
providing at least one vasoconstrictor;
applying the at least one therapeutic compound and at least one vasoconstrictor to the nasal cavity of a patient;
delivering the at least one therapeutic compound to the target; and
reducing the amount of the at least one therapeutic compound that is absorbed into the blood and/or peripheral tissues.

### Claim 19 (depends on 18)

The method of claim 18, wherein the condition comprises meningitis and/or encephalitis.

### Claim 20

An intranasally administered pharmaceutical compound for increasing the efficiency of intranasal delivery of at least one pharmaceutical compound to a target within a patient's central nervous system for treatment of a disease or condition of the patient, comprising:
an effective amount of at least one vasoconstrictor; and
an effective amount of at least one therapeutic compound, wherein the pharmaceutical compound is administered intranasally and delivered to the target with limited absorption of the pharmaceutical composition into the blood and/or peripheral tissues.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the target comprises the patient's central nervous system.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the patient condition comprises Alzheimer's disease.

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the patient condition comprises Parkinson's disease.

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein the patient condition comprises one or more of the following: cerebrovascular disorders, frontotemporal dementia, personality disorders, cognition disorders, motor dysfunction, eating disorders, sleep disorders, affective disorders, anxiety disorders, schizophrenia, brain tumors and ataxia.

### Claim 25 (depends on 21)

The pharmaceutical composition of claim 21, wherein the target comprises the frontal cortex.

### Claim 26 (depends on 21)

The pharmaceutical composition of claim 21, wherein the target comprises the hippocampus.

### Claim 27 (depends on 21)

The pharmaceutical composition of claim 21, wherein the target comprises the hypothalamus.

### Claim 28 (depends on 21)

The pharmaceutical composition of claim 21, wherein the target comprises the cerebellum and brainstem.

### Claim 29 (depends on 21)

The pharmaceutical composition of claim 21, wherein the at least one therapeutic compound comprises deferoxamine.

### Claim 30 (depends on 21)

The pharmaceutical composition of claim 21, wherein the at least one therapeutic compound comprises one or more of the following: insulin, IGF-I, TGFbeta, IL1beta, TNFalpha, TGFbeta, cobalt, pyruvate, oxalacetate and lactate.

### Claim 31 (depends on 21)

The pharmaceutical composition of claim 21, wherein the at least one therapeutic compound comprises one or more of the following: HC and KTP.

### Claim 32 (depends on 21)

The pharmaceutical composition of claim 21, wherein the at least one vasoconstrictor comprises PHE and THZ.

### Claim 33 (depends on 20)

The pharmaceutical composition of claim 20, wherein the condition comprises brain tumors and the method further comprises treating and/or preventing brain tumors.

### Claim 34 (depends on 20)

The pharmaceutical composition of claim 20, wherein the target comprises the patient's lymphatic system.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, wherein the condition comprises one or more of the following: multiple myeloma, Hodgkin's disease, lymphadenitis, lymphatic filariasis, lymphoma, non-Hodgkin's lymphoma, and thymus cancer.

### Claim 36 (depends on 34)

The pharmaceutical composition of claim 34, wherein the condition comprises one or more of the following: AIDS, neuroAIDS, SCID, autoimmune diseases, Sjogren's syndrome, lupus and multiple sclerosis.

### Claim 37 (depends on 34)

The pharmaceutical composition of claim 34, wherein the condition comprises allergies and/or chronic sinusitis.

### Claim 38 (depends on 20)

The pharmaceutical composition of claim 20, wherein the target comprises the patient's meninges.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, wherein the condition comprises meningitis and/or encephalitis.
